Session themes:

• Mechanisms of Insulin Resistance
• Lipolysis and Insulin Resistance
• Fatty liver
• Population science
• Inflammation/Reactive Oxygen Species
• Pharmaceutical Perspectives

Confirmed speakers:

• Kendra Bence, Pfizer, USA
• Jens Brüning, Max Planck Institute for Metabolism Research, Germany
• Sheila Collins, Vanderbilt University Medical Center, USA
• Anthony W Ferrante, Noami Berrie Diabetes Center, USA
• Gerald Shulman, Yale Diabetes Research Center, USA
• David James, University of Sydney, Australia
• James Johnson, University of British Columbia, Vancouver, Canada
• Barbara Kahn, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
• Fredrik Karpe, Oxford Centre for Diabetes, Endocrinology and Metabolism, UK
• Dominique Langin, Metabolic and Cardiovascular Research Institute, INSERM, France
• Ruth Loos, Icahn School of Medicine, Mount Sinai, New York, USA
• Luca Lotta, Regeneron Pharmaceutical Inc, USA
• Bettina Mittendorfer, Washington University, USA
• Catherine Postic, Institut Cochin, France
• Ethan Weiss, Third Rock Ventures, USA
• Hannele Yki-Järvinen, University of Helsinki, Finland
• Anja Ziegerer, Helmholtz Munich, Germany

Detailed programme to follow

Scientific Organisers

Professor Sir Stephen O’Rahilly  

Stephen is a Director at the MRC Metabolic Diseases Unit and Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge.  He is also the Scientific Director of the NIHR Biomedical Research Centre and Head of Department of Clinical Biochemistry, University of Cambridge. His main research area is the aetiology and pathophysiology of human metabolic and endocrine disease and how such information might be used to improve the diagnosis, therapy and prevention of these diseases.

Professor David Savage 

Having completed his medical training in South Africa, David moved to the UK in 2000 to take up a research post in Cambridge. His research has focussed on understanding the molecular pathogenesis of lipodystrophies and insulin resistance. To this end, his group engages in human, model organism and cellular studies. He is currently based at the Wellcome-MRC Institute of Metabolic Science, at the University of Cambridge.